Replies to post #192163 on Biotech Values

[DewDiligence]

BXLT selling $5B of debt (to prepare for 7/1/15 separation from BAX):

http://finance.yahoo.com/news/baxalta-announces-pricing-5-billion-120000006.html

[DewDiligence]

BXLT, KMDA ink clinical-trial collaboration to test AAT for prevention of lung-transplant rejection:

http://finance.yahoo.com/news/kamada-collaborates-baxalta-phase-1-103000657.html

p.s. BXLT, which will be formally spun off from BAX on 7/1/15, is now trading on a “when issued” basis (http://finance.yahoo.com/q?s=BXLT-WI&ql=0 ).

[DewDiligence]

BXLT—New interim data on Factor-IX gene therapy (BAX335):

http://finance.yahoo.com/news/baxalta-reports-continued-progress-phase-130000765.html

All told, I think these data are modestly bearish due to the neutralizing immune response in the high-dose cohort. @BioTerp has a fairly detailed discussion at: http://goo.gl/2isCTO .

[DewDiligence]

BXLT—pharma spin-off from BAX—launches as independent company:

http://finance.yahoo.com/news/baxalta-launches-global-biopharmaceutical-leader-110000234.html

Please see #msg-114360736 for background info.

[DewDiligence]

BXLT, which has existed for only 28 days, authorizes a $1B buyback plan:

http://finance.yahoo.com/news/baxalta-board-directors-declares-inaugural-200600080.html

[DewDiligence]

Third Point discloses ~10% stake in BAX—seeks BoD representation:

http://www.bloomberg.com/news/articles/2015-08-05/third-point-exits-1-billion-alibaba-stake-adds-mckesson

Loeb, whose firm has almost a 10 percent stake including amassed options it’s converting into stock, applauded the company’s recent spinoff of its Baxalta Inc. pharmaceutical business, and for announcing a succession plan for current CEO Robert Parkinson. Third Point, which oversees about $18 billion, said it has more than $2 billion in economic exposure to Baxter.

…Loeb described Baxter’s staggered board as “shareholder unfriendly and archaic,” where only a few directors are up for re-election each year, and its “odd voting structure that values shareholders individually rather than according to economic interest.”

[DewDiligence]

(BAX competition)—Debiopharm, FMS ink collaboration to develop PD systems:

http://finance.yahoo.com/news/debiotech-fresenius-medical-care-announce-070000483.html

Debiotech SA…and Fresenius Medical Care, the world's largest provider of dialysis products and services, announced today they have entered into an exclusive partnership to develop a portfolio of state-of-the-art peritoneal dialysis (PD) technologies. This partnership will bring Debiotech's specialized expertise to the dialysis industry.

PD is a pretty big part of BAX’s business.

[DewDiligence]

BXLT presents ASH lineup:

http://finance.yahoo.com/news/baxalta-showcase-innovation-leadership-hematology-114500243.html